CareDx announces landmark data in AI-powered transplant diagnostics
CareDx, Inc. announced the presentation of several high-impact studies and digital health innovations by independent research teams at the 2025 World Transplant Congress (WTC), demonstrating advances in artificial intelligence, predictive diagnostics, transplant access, and organ-specific innovation.
These featured abstracts are part of more than 40 CareDx-featured presentations spanning kidney, lung, liver, and heart transplantation accepted at WTC 2025. The studies reflect the growing body of evidence supporting the clinical utility of CareDx technologies.
The company also announced the launch of AlloSure Plus (formerly AlloView), an AI-driven diagnostic platform that integrates AlloSure donor-derived cell-free DNA (dd-cfDNA) analysis with traditional tools to provide a personalized risk of rejection. An international, prospective study led by the Paris Transplant Group validated AlloSure Plus to identify organ rejection using over 2,700 renal transplant biopsies. AlloSure Plus will be integrated with AlloSure results through EPIC Aura at initial launch sites in the third quarter of 2025 ahead of a broader rollout.
Featured abstract highlights:
- Abstract OA33.3: Performance of Integrative dd-cfDNA in Detecting Rejection Based on the Updated Banff 2022 Classification: With over 4,100 biopsies analyzed, this study found that AI-powered AlloSure Plus showed improved sensitivity and specificity for detecting rejection, including microvascular inflammation, an emerging hallmark of antibody-mediated rejection (AMR).
- Abstract OA59.4: Renal Transplant Recipients with Elevated Donor-Derived Cell-Free DNA Are at Increased Risk of Graft Loss: Data from 1,258 patients in the KOAR registry revealed that kidney transplant recipients with elevated dd-cfDNA had an 8.166-fold increased risk of graft loss at 3 years, underscoring dd-cfDNA’s long-term prognostic value and potential for guiding early intervention.
- Abstract P3.07.183: Longitudinal dd-cfDNA Kinetics in Recipients of Hard-to-Place Kidneys: In a cohort of 56 recipients of high-risk, hard-to-place kidneys, longitudinal AlloSure dd-cfDNA monitoring showed consistently low levels and excellent graft survival, supporting broader utilization of marginal organs and the role of dd-cfDNA in post-transplant surveillance.
- Abstract OA36.8: Impact of Persistently Elevated Simultaneous Gene Expression Profiling and Donor-Derived Cell-Free DNA on Future Clinical Events: Among 2,240 heart transplant recipients (included from the Surveillance HeartCare Outcomes Registry (SHORE)), those with persistently elevated gene expression profiling (AlloMap) and dd-cfDNA (AlloSure) were nearly twice as likely to experience rejection, graft dysfunction, or cardiovascular death, highlighting the prognostic power of multimodal surveillance.
